Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Income (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Net Income for 16 consecutive years, with $52.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 5.79% year-over-year to $52.7 million, compared with a TTM value of $214.3 million through Dec 2025, up 30.78%, and an annual FY2025 reading of $214.3 million, up 30.78% over the prior year.
  • Net Income was $52.7 million for Q4 2025 at Catalyst Pharmaceuticals, roughly flat from $52.8 million in the prior quarter.
  • Across five years, Net Income topped out at $56.7 million in Q1 2025 and bottomed at -$30.8 million in Q3 2023.
  • Average Net Income over 5 years is $28.6 million, with a median of $26.4 million recorded in 2023.
  • The sharpest move saw Net Income surged 364.43% in 2022, then plummeted 235.24% in 2023.
  • Year by year, Net Income stood at $9.3 million in 2021, then soared by 364.43% to $43.2 million in 2022, then plummeted by 60.59% to $17.0 million in 2023, then skyrocketed by 228.28% to $55.9 million in 2024, then decreased by 5.79% to $52.7 million in 2025.
  • Business Quant data shows Net Income for CPRX at $52.7 million in Q4 2025, $52.8 million in Q3 2025, and $52.1 million in Q2 2025.